{"id":"cefuroxime","rwe":[{"pmid":"41902618","year":"2026","title":"Detection of Listeria monocytogenes from Raw Milk (Nono) in Cows Using Polymerase Chain Reaction.","finding":"","journal":"Foodborne pathogens and disease","studyType":"Clinical Study"},{"pmid":"41892449","year":"2026","title":"Analysis of Antibiotic Consumption Trends and Pathogens' Epidemiological Profile Within a Multidisciplinary Clinical Hospital from Romania.","finding":"","journal":"Antibiotics (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41891536","year":"2026","title":"Investigation of interactions between LDPE containers and ingredients of oil-based ophtalmic formulations.","finding":"","journal":"Polimery w medycynie","studyType":"Clinical Study"},{"pmid":"41867320","year":"2026","title":"Case Report: Maculopathy following standard dose intracameral cefuroxime injection during ICL surgery.","finding":"","journal":"Frontiers in ophthalmology","studyType":"Clinical Study"},{"pmid":"41860599","year":"2026","title":"Dual-mode carbon dots for cefuroxime monitoring in plasma.","finding":"","journal":"Mikrochimica acta","studyType":"Clinical Study"}],"_fda":{"id":"98c257e2-f4e7-4786-bad3-fabbd0081ada","set_id":"0303526e-6781-4d38-adf9-13903722d937","openfda":{"unii":["Z49QDT0J8Z"],"route":["ORAL"],"rxcui":["309097"],"spl_id":["98c257e2-f4e7-4786-bad3-fabbd0081ada"],"brand_name":["Cefuroxime axetil"],"spl_set_id":["0303526e-6781-4d38-adf9-13903722d937"],"package_ndc":["63629-9446-1"],"product_ndc":["63629-9446"],"generic_name":["CEFUROXIME AXETIL"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["CEFUROXIME AXETIL"],"manufacturer_name":["Bryant Ranch Prepack"],"application_number":["ANDA065496"],"original_packager_product_ndc":["67877-215"]},"version":"101","pregnancy":["8.1 Pregnancy Risk Summary Available data from published epidemiologic studies, case series, and case reports over several decades with cephalosporin use, including cefuroxime axetil, in pregnant women have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data) . In studies in pregnant mice and rats administered oral cefuroxime axetil during organogenesis at 14 and 9 times the maximum recommended human dose (MRHD) based on body surface area, respectively, there were no adverse developmental outcomes (see Data). The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk: Maternal gonorrhea may be associated with preterm birth, low neonatal birth weight, chorioamnionitis, intrauterine growth restriction, small for gestational age, and premature rupture of membranes. Perinatal transmission of gonorrhea to the offspring can result in infant blindness, joint infections, and bloodstream infections. Data Human Data: While available studies cannot definitively establish the absence of risk, published data from epidemiologic studies, case series, and case reports over several decades have not identified an association with cephalosporin use (including cefuroxime axetil) during pregnancy and major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Available studies have methodologic limitations, including small sample size, retrospective data collection, and inconsistent comparator groups. Animal Data: Studies performed with oral cefuroxime axetil administered to pregnant mice during organogenesis (Gestation Days 7 through 16) at doses up to 3,200 mg/kg/day (14 times the MRHD based on body surface area); and in rats dosed during organogenesis and lactation (Gestation Days 7 through 16 and Gestation Days 17 through Lactation Day 21, respectively) at doses up to 1,000 mg/kg/day (9 times the MRHD based on body surface area) have revealed no adverse developmental outcomes."],"overdosage":["10 OVERDOSAGE Overdosage of cephalosporins can cause cerebral irritation leading to convulsions or encephalopathy. Serum levels of cefuroxime can be reduced by hemodialysis and peritoneal dialysis."],"description":["11 DESCRIPTION Cefuroxime axetil tablets, USP contain cefuroxime as cefuroxime axetil. Cefuroxime axetil is a semisynthetic, cephalosporin antibacterial drug for oral administration. The chemical name of cefuroxime axetil (1-(acetyloxy) ethyl ester of cefuroxime) is ( RS )-1 hydroxyethyl (6 R ,7 R )-7-[2-(2-furyl)glyoxyl-amido]-3-(hydroxymethyl)-8-oxo-5-thia-1 azabicyclo[4.2.0]-oct-2-ene-2-carboxylate, 72-( Z )-( O -methyl-oxime), 1-acetate 3-carbamate. Its molecular formula is C 20 H 22 N 4 O 10 S, and it has a molecular weight of 510.48. Cefuroxime axetil is in the amorphous form and has the following structural formula: Cefuroxime axetil tablets, USP are film-coated and contain the equivalent of 250 or 500 mg of cefuroxime as cefuroxime axetil. Cefuroxime axetil tablets, USP contain the inactive ingredients microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide, calcium stearate, calcium carbonate, crospovidone, hypromellose, titanium dioxide, propylene glycol, FD &C blue no.1 Aluminium lake."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Cefuroxime axetil tablets,USP 250 mg of cefuroxime (as cefuroxime axetil), are blue, capsule-shaped, biconvex, film-coated tablets with ''204\" debossed on one side and plain on the other side as follows: 20 Tablets/Bottle NDC 63629-9446-1 Store at 20° to 25°C (68° to 77°F). [See USP controlled room temperature]. Replace cap securely after each opening."],"geriatric_use":["8.5 Geriatric Use Of the total number of subjects who received cefuroxime axetil in 20 clinical trials, 375 were aged 65 and older while 151 were aged 75 and older. No overall differences in safety or effectiveness were observed between these subjects and younger adult subjects. Reported clinical experience has not identified differences in responses between the elderly and younger adult patients, but greater sensitivity of some older individuals cannot be ruled out. Cefuroxime is substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of cefuroxime axetil have been established for pediatric patients aged 3 months to 12 years for acute bacterial maxillary sinusitis based upon its approval in adults. Use of cefuroxime axetil in pediatric patients is supported by pharmacokinetic and safety data in adults and pediatric patients, and by clinical and microbiological data from adequate and well-controlled trials of the treatment of acute bacterial maxillary sinusitis in adults and of acute otitis media with effusion in pediatric patients. It is also supported by postmarketing adverse events surveillance. [See Indications and Usage ( 1 ), Dosage and Administration ( 2 ), Adverse Reactions (6), Clinical Pharmacology ( 12.3 ).]"],"effective_time":"20230316","clinical_studies":["14 CLINICAL STUDIES 14.1 Acute Bacterial Maxillary Sinusitis One adequate and well-controlled trial was performed in subjects with acute bacterial maxillary sinusitis. In this trial, each subject had a maxillary sinus aspirate collected by sinus puncture before treatment was initiated for presumptive acute bacterial sinusitis. All subjects had radiographic and clinical evidence of acute maxillary sinusitis. In the trial, the clinical effectiveness of cefuroxime axetil in treating acute maxillary sinusitis was comparable to an oral antimicrobial agent containing a specific β-lactamase inhibitor. However, microbiology data demonstrated cefuroxime axetil to be effective in treating acute bacterial maxillary sinusitis due only to Streptococcus pneumoniae or non-β-lactamase–producing Haemophilus influenzae. Insufficient numbers of β-lactamase–producing Haemophilus influenzae and Moraxella catarrhalis isolates were obtained in this trial to adequately evaluate the effectiveness of cefuroxime axetil in treating acute bacterial maxillary sinusitis due to these 2 organisms. This trial randomized 317 adult subjects, 132 subjects in the U.S. and 185 subjects in South America. Table 10 shows the results of the intent-to-treat analysis. Table 10. Clinical Effectiveness of Cefuroxime Axetil Tablets in the Treatment of Acute Bacterial Maxillary Sinusitis U.S. Subjects a South American Subjects b Cefuro xime Axetil Tablets 250 mg Twice Daily (n = 49) Control c (n = 43) Cefuroxime Axetil Tablets 250 mg Twice Daily (n = 49) Controlc (n = 43) Clinical success (cure + improvement) 65% 53% 77% 74% Clinical cure 53% 44% 72% 64% Clinical improvement 12% 9% 5% 10% a 95% confidence interval around the success difference [-0.08, +0.32]. b 95% confidence interval around the success difference [-0.10, +0.16]. c Control was an antibacterial drug containing a β-lactamase inhibitor. In this trial and in a supporting maxillary puncture trial, 15 evaluable subjects had non-β-lactamase–producing Haemophilus influenzae as the identified pathogen. Of these, 67% (10/15) had this pathogen eradicated. Eighteen (18) evaluable subjects had Streptococcus pneumoniae as the identified pathogen. Of these, 83% (15/18) had this pathogen eradicated. 14.2 Early Lyme Disease Two adequate and well-controlled trials were performed in subjects with early Lyme disease. All subjects presented with physician-documented erythema migrans, with or without systemic manifestations of infection. Subjects were assessed at 1 month posttreatment for success in treating early Lyme disease (Part I) and at 1 year posttreatment for success in preventing the progression to the sequelae of late Lyme disease (Part II). A total of 355 adult subjects (181 treated with cefuroxime axetil and 174 treated with doxycycline) were randomized in the 2 trials, with diagnosis of early Lyme disease confirmed in 79% (281/355). The clinical diagnosis of early Lyme disease in these subjects was validated by 1) blinded expert reading of photographs, when available, of the pretreatment erythema migrans skin lesion, and 2) serologic confirmation (using enzyme-linked immunosorbent assay [ELISA] and immunoblot assay [“Western” blot]) of the presence of antibodies specific to Borrelia burgdorferi , the etiologic agent of Lyme disease. The efficacy data in Table 11 are specific to this “validated” patient subset, while the safety data below reflect the entire patient population for the 2 trials. Clinical data for evaluable subjects in the “validated” patient subset are shown in Table 11. Table 11. Clinical Effectiveness of Cefuroxime Axetil Tablets Compared with Doxycycline in the Treatment of Early Lyme Disease Part I (1 Month after 20 Days of Treatment) a Part II (1 Year after 20 Days of Treatment) b Cefuroxime Axetil Tablets 500 mg Twice Daily (n = 125) Doxycycline 100 mg 3 Times Daily (n = 108) Cefuroxime Axetil Tablets 500 mg Twice Daily (n = 105c) Doxycycline 100 mg 3 Times Daily (n = 83c) Satisfactory clinical outcomed 91% 93% 84% 87% Clinical cure/success 72% 73% 73% 73% Clinical improvement 19% 19% 10% 13% a 95% confidence interval around the satisfactory difference for Part I (-0.08, +0.05). b 95% confidence interval around the satisfactory difference for Part II (-0.13, +0.07). c n’s include subjects assessed as unsatisfactory clinical outcomes (failure + recurrence) in Part I (cefuroxime axetil - 11 [5 failure, 6 recurrence]; doxycycline - 8 [6 failure, 2 recurrence]). d Satisfactory clinical outcome includes cure + improvement (Part I) and success + improvement (Part II). Cefuroxime axetil and doxycycline were effective in prevention of the development of sequelae of late Lyme disease. While the incidence of drug-related gastrointestinal adverse reactions was similar in the 2 treatment groups (cefuroxime axetil - 13%; doxycycline - 11%), the incidence of drug-related diarrhea was higher in the cefuroxime axetil arm versus the doxycycline arm (11% versus 3%, respectively)."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption After oral administration, cefuroxime axetil is absorbed from the gastrointestinal tract and rapidly hydrolyzed by nonspecific esterases in the intestinal mucosa and blood to cefuroxime. Serum pharmacokinetic parameters for cefuroxime following administration of cefuroxime axetil tablets to adults are shown in Table 8. Table 8. Pharmacokinetics of Cefuroxime Administered in the Postprandial State as Cefuroxime Axetil Tablets to Adults a Doseb (Cefuroxime Equivalent) Peak Plasma Concentration (mcg/mL) Time of Peak Plasma Concentration (h) Mean Elimination Half-life (h) AUC (mcg•h/mL) 125 mg 2.1 2.2 1.2 6.7 250 mg 4.1 2.5 1.2 12.9 500 mg 7 3 1.2 27.4 1,000 mg 13.6 2.5 1.3 50 a Mean values of 12 healthy adult volunteers. b Drug administered immediately after a meal. Effect of Food: Absorption of the tablet is greater when taken after food (absolute bioavailability increases from 37% to 52%). Despite this difference in absorption, the clinical and bacteriologic responses of subjects were independent of food intake at the time of tablet administration in 2 trials where this was assessed. All pharmacokinetic and clinical effectiveness and safety trials in pediatric subjects using the suspension formulation were conducted in the fed state. No data are available on the absorption kinetics of the suspension formulation when administered to fasted pediatric subjects. Lack of Bioequivalence : Oral suspension was not bioequivalent to tablets when tested in healthy adults. The tablet and oral suspension formulations are NOT substitutable on a milligram-per-milligram basis. The area under the curve for the suspension averaged 91% of that for the tablet, and the peak plasma concentration for the suspension averaged 71% of the peak plasma concentration of the tablets. Therefore, the safety and effectiveness of both the tablet and oral suspension formulations were established in separate clinical trials. Distribution Cefuroxime is distributed throughout the extracellular fluids. Approximately 50% of serum cefuroxime is bound to protein. Metabolism The axetil moiety is metabolized to acetaldehyde and acetic acid. Excretion Cefuroxime is excreted unchanged in the urine; in adults, approximately 50% of the administered dose is recovered in the urine within 12 hours. The pharmacokinetics of cefuroxime in pediatric subjects have not been studied. Until further data are available, the renal elimination of cefuroxime axetil established in adults should not be extrapolated to pediatric subjects. Specific Populations Patients with Renal Impairment: In a trial of 28 adults with normal renal function or severe renal impairment (creatinine clearance <30 mL/min), the elimination half-life was prolonged in relation to severity of renal impairment. Prolongation of the dosage interval is recommended in adult patients with creatinine clearance <30 mL/min [see Dosage and Administration ( 2.5 )]. Geriatric Patients : In a trial of 20 elderly subjects (mean age = 83.9 years) having a mean creatinine clearance of 34.9 mL/min, the mean serum elimination half-life was prolonged to 3.5 hours; however, despite the lower elimination of cefuroxime in geriatric patients, dosage adjustment based on age is not necessary [see Use in Specific Populations ( 8.5 )]. Drug Interaction Studies Concomitant administration of probenecid with cefuroxime axetil tablets increases the cefuroxime area under the serum concentration versus time curve and maximum serum concentration by 50% and 21%, respectively [see Drug Interactions( 7.2 )]."],"adverse_reactions":["6 ADVERSE REACTIONS The following serious and otherwise important adverse reaction is described in greater detail in the Warnings and Precautions section of the label: Anaphylactic Reactions [see Warnings and Precautions ( 5.1 )]. The most common adverse reactions (≥3%) for cefuroxime axetil tablets are diarrhea, nausea/vomiting, Jarisch-Herxheimer reaction, and vaginitis (early Lyme disease). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Ascend Laboratories, LLC at 1-877-ASC-RX01 (877-272-7901) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. Tablets Multiple-Dose Dosing Regimens with 7 to 10 Days’ Duration : In multiple-dose clinical trials, 912 subjects were treated with cefuroxime axetil (125 to 500 mg twice daily). It is noted that 125 mg twice daily is not an approved dosage. Twenty (2.2%) subjects discontinued medication due to adverse reactions. Seventeen (85%) of the 20 subjects who discontinued therapy did so because of gastrointestinal disturbances, including diarrhea, nausea, vomiting, and abdominal pain. The percentage of subjects treated with cefuroxime axetil who discontinued study drug because of adverse reactions was similar at daily doses of 1,000, 500, and 250 mg (2.3%, 2.1%, and 2.2%, respectively). However, the incidence of gastrointestinal adverse reactions increased with the higher recommended doses. The adverse reactions in Table 5 are for subjects (n = 912) treated with cefuroxime axetil in multiple-dose clinical trials. Table 5. Adverse Reactions (≥1%) after Multiple-Dose Regimens with Cefuroxime Axetil Tablets Adverse Reaction Cefuroxime Axetil (n = 912) Blood and lymphatic system disorders Eosinophilia 1% Gastrointestinal disorders Diarrhea 4% Nausea/Vomiting 3% Investigations Transient elevation in AST 2% Transient elevation in ALT 2% Transient elevation in LDH 1% The following adverse reactions occurred in less than 1% but greater than 0.1% of subjects (n = 912) treated with cefuroxime axetil in multiple-dose clinical trials. Immune System Disorders: Hives, swollen tongue. Metabolism and Nutrition Disorders: Anorexia. Nervous System Disorders: Headache. Cardiac Disorders: Chest pain. Respiratory Disorders: Shortness of breath. Gastrointestinal Disorders: Abdominal pain, abdominal cramps, flatulence, indigestion, mouth ulcers. Skin and Subcutaneous Tissue Disorders: Rash, itch. Renal and Urinary Disorders: Dysuria. Reproductive System and Breast Disorders: Vaginitis, vulvar itch. General Disorders and Administration Site Conditions: Chills, sleepiness, thirst. Investigations: Positive Coombs’ test. Early Lyme Disease with 20-Day Regimen: Two multicenter trials assessed cefuroxime axetil tablets 500 mg twice daily for 20 days. The most common drug-related adverse experiences were diarrhea (10.6%), Jarisch-Herxheimer reaction (5.6%), and vaginitis (5.4%). Other adverse experiences occurred with frequencies comparable to those reported with 7 to 10 days’ dosing. Single-Dose Regimen for Uncomplicated Gonorrhea: In clinical trials using a single 1,000-mg dose of cefuroxime axetil, 1,061 subjects were treated for uncomplicated gonorrhea. The adverse reactions in Table 6 were for subjects treated with a single dose of 1,000 mg cefuroxime axetil in U.S. clinical trials. Table 6. Adverse Reactions (≥1%) after Single-Dose Regimen with 1,000-mg Cefuroxime Axetil Tablets for Uncomplicated Gonorrhea Adverse Reaction Cefuroxime axetil (n = 1,061) Gastrointestinal disorders Nausea/Vomiting 7% Diarrhea 4% The following adverse reactions occurred in less than 1% but greater than 0.1% of subjects (n = 1,061) treated with a single dose of cefuroxime axetil 1,000 mg for uncomplicated gonorrhea in U.S. clinical trials. Infections and Infestations: Vaginal candidiasis. Nervous System Disorders: Headache, dizziness, somnolence. Cardiac Disorders: Tightness/pain in chest, tachycardia. Gastrointestinal Disorders: Abdominal pain, dyspepsia. Skin and Subcutaneous Tissue Disorders: Erythema, rash, pruritus. Musculoskeletal and Connective Tissue Disorders: Muscle cramps, muscle stiffness, muscle spasm of neck, lockjaw-type reaction. Renal and Urinary Disorders: Bleeding/pain in urethra, kidney pain. Reproductive System and Breast Disorders: Vaginal itch, vaginal discharge. 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of cefuroxime axetil. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and Lymphatic System Disorders Hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia. Gastrointestinal Disorders Pseudomembranous colitis [see Warnings and Precautions (5.2)] . Hepatobiliary Disorders Hepatic impairment including hepatitis and cholestasis, jaundice. Immune System Disorders Anaphylaxis, serum sickness-like reaction, acute myocardial ischemia with or without myocardial infarction may occur as part of an allergic reaction. Investigations Increased prothrombin time. Nervous System Disorders Seizure, encephalopathy. Renal and Urinary Disorders Renal dysfunction. Skin and Subcutaneous Tissue Disorders Angioedema, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria."],"contraindications":["4 CONTRAINDICATIONS Cefuroxime axetil is contraindicated in patients with a known hypersensitivity (e.g., anaphylaxis) to cefuroxime axetil or to other β-lactam antibacterial drugs (e.g., penicillins and cephalosporins). Known hypersensitivity (e.g., anaphylaxis) to cefuroxime axetil or to other β-lactams (e.g., penicillins and cephalosporins)."],"drug_interactions":["7 DRUG INTERACTIONS Drugs that reduce gastric acidity may lower the bioavailability of cefuroxime axetil. ( 7.1 ) Coadministration with probenecid increases systemic exposure to cefuroxime axetil and is therefore not recommended. ( 7.2 ) 7.1 Drugs that Reduce Gastric Acidity Drugs that reduce gastric acidity may result in a lower bioavailability of cefuroxime axetil compared with administration in the fasting state. Administration of drugs that reduce gastric acidity may negate the food effect of increased absorption of cefuroxime axetil when administered in the postprandial state. Administer cefuroxime axetil at least 1 hour before or 2 hours after administration of short-acting antacids. Histamine-2 (H2) antagonists and proton pump inhibitors should be avoided. 7.2 Probenecid Concomitant administration of probenecid with cefuroxime axetil tablets increases serum concentrations of cefuroxime [see Clinical Pharmacology ( 12.3 )]. Coadministration of probenecid with cefuroxime axetil is not recommended. 7.3 Drug/Laboratory Test Interactions A false-positive reaction for glucose in the urine may occur with copper reduction tests (e.g., Benedict's or Fehling's solution), but not with enzyme-based tests for glycosuria. As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood/plasma glucose levels in patients receiving cefuroxime axetil. The presence of cefuroxime does not interfere with the assay of serum and urine creatinine by the alkaline picrate method."],"mechanism_of_action":["12.1 Mechanism of Action Cefuroxime axetil is an antibacterial drug [see Microbiology ( 12.4 )]."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Cefuroxime axetil is an antibacterial drug [see Microbiology ( 12.4 )]. 12.3 Pharmacokinetics Absorption After oral administration, cefuroxime axetil is absorbed from the gastrointestinal tract and rapidly hydrolyzed by nonspecific esterases in the intestinal mucosa and blood to cefuroxime. Serum pharmacokinetic parameters for cefuroxime following administration of cefuroxime axetil tablets to adults are shown in Table 8. Table 8. Pharmacokinetics of Cefuroxime Administered in the Postprandial State as Cefuroxime Axetil Tablets to Adults a Doseb (Cefuroxime Equivalent) Peak Plasma Concentration (mcg/mL) Time of Peak Plasma Concentration (h) Mean Elimination Half-life (h) AUC (mcg•h/mL) 125 mg 2.1 2.2 1.2 6.7 250 mg 4.1 2.5 1.2 12.9 500 mg 7 3 1.2 27.4 1,000 mg 13.6 2.5 1.3 50 a Mean values of 12 healthy adult volunteers. b Drug administered immediately after a meal. Effect of Food: Absorption of the tablet is greater when taken after food (absolute bioavailability increases from 37% to 52%). Despite this difference in absorption, the clinical and bacteriologic responses of subjects were independent of food intake at the time of tablet administration in 2 trials where this was assessed. All pharmacokinetic and clinical effectiveness and safety trials in pediatric subjects using the suspension formulation were conducted in the fed state. No data are available on the absorption kinetics of the suspension formulation when administered to fasted pediatric subjects. Lack of Bioequivalence : Oral suspension was not bioequivalent to tablets when tested in healthy adults. The tablet and oral suspension formulations are NOT substitutable on a milligram-per-milligram basis. The area under the curve for the suspension averaged 91% of that for the tablet, and the peak plasma concentration for the suspension averaged 71% of the peak plasma concentration of the tablets. Therefore, the safety and effectiveness of both the tablet and oral suspension formulations were established in separate clinical trials. Distribution Cefuroxime is distributed throughout the extracellular fluids. Approximately 50% of serum cefuroxime is bound to protein. Metabolism The axetil moiety is metabolized to acetaldehyde and acetic acid. Excretion Cefuroxime is excreted unchanged in the urine; in adults, approximately 50% of the administered dose is recovered in the urine within 12 hours. The pharmacokinetics of cefuroxime in pediatric subjects have not been studied. Until further data are available, the renal elimination of cefuroxime axetil established in adults should not be extrapolated to pediatric subjects. Specific Populations Patients with Renal Impairment: In a trial of 28 adults with normal renal function or severe renal impairment (creatinine clearance <30 mL/min), the elimination half-life was prolonged in relation to severity of renal impairment. Prolongation of the dosage interval is recommended in adult patients with creatinine clearance <30 mL/min [see Dosage and Administration ( 2.5 )]. Geriatric Patients : In a trial of 20 elderly subjects (mean age = 83.9 years) having a mean creatinine clearance of 34.9 mL/min, the mean serum elimination half-life was prolonged to 3.5 hours; however, despite the lower elimination of cefuroxime in geriatric patients, dosage adjustment based on age is not necessary [see Use in Specific Populations ( 8.5 )]. Drug Interaction Studies Concomitant administration of probenecid with cefuroxime axetil tablets increases the cefuroxime area under the serum concentration versus time curve and maximum serum concentration by 50% and 21%, respectively [see Drug Interactions( 7.2 )]. 12.4 Microbiology Mechanism of Action Cefuroxime axetil is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefuroxime axetil has activity in the presence of some β-lactamases, both penicillinases and cephalosporinases, of gram-negative and gram-positive bacteria. Resistance Resistance to cefuroxime axetil is primarily through hydrolysis by β-lactamase, alteration of penicillin-binding proteins (PBPs), decreased permeability, and the presence of bacterial efflux pumps. Susceptibility to cefuroxime axetil will vary with geography and time; local susceptibility data should be consulted, if available. Beta-lactamase - negative, ampicillin-resistant (BLNAR) isolates of H. influenzae should be considered resistant to cefuroxime axetil. Antimicrobial Activity Cefuroxime axetil has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections [see Indications and Usage ( 1 )] : Aerobic Bacteria: Gram-positive bacteria • Staphylococcus aureus (methicillin-susceptible isolates only) • Streptococcus pneumoniae • Streptococcus pyogenes Gram-negative bacteria • Escherichia colia • Klebsiella pneumoniaea • Haemophilus influenzae • Haemophilus parainfluenzae • Moraxella catarrhalis • Neisseria gonorrhoeae a Most extended spectrum β-lactamase (ESBL)-producing and carbapenemase-producing isolates are resistant to cefuroxime axetil. Spirochetes • Borrelia burgdorferi The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for cefuroxime against isolates of similar genus or organism group. However, the efficacy of cefuroxime axetil in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials. Aerobic Bacteria: Gram-positive bacteria • Staphylococcus epidermidis (methicillin-susceptible isolates only) • Staphylococcus saprophyticus (methicillin-susceptible isolates only) • Streptococcus agalactiae Gram-negative bacteria • Morganella morganii • Proteus inconstans • Proteus mirabilis • Providencia rettgeri Anaerobic Bacteria : Gram-positive bacteria • Peptococcus niger Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC."],"indications_and_usage":["1 INDICATIONS AND USAGE Cefuroxime axetil tablet is a cephalosporin antibacterial drug indicated for the treatment of the following infections due to susceptible bacteria: (1) Pharyngitis/tonsillitis (adults and pediatric patients) ( 1.1 ) Acute bacterial otitis media (pediatric patients) ( 1.2 ) Acute bacterial maxillary sinusitis (adults and pediatric patients) ( 1.3 ) Acute bacterial exacerbations of chronic bronchitis (adults and pediatric patients 13 years and older) ( 1.4 ) Uncomplicated skin and skin-structure infections (adults and pediatric patients 13 years and older) ( 1.5 ) Uncomplicated urinary tract infections (adults and pediatric patients 13 years and older) ( 1.6 ) Uncomplicated gonorrhea (adults and pediatric patients 13 years and older) ( 1.7 ) Early Lyme disease (adults and pediatric patients 13 years and older) ( 1.8 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. 1.1 Pharyngitis/Tonsillitis Cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of Streptococcus pyogenes . Limitations of Use The efficacy of cefuroxime axetil in the prevention of rheumatic fever was not established in clinical trials. The efficacy of cefuroxime axetil in the treatment of penicillin-resistant strains of Streptococcus pyogenes has not been demonstrated in clinical trials. 1.2 Acute Bacterial Otitis Media Cefuroxime axetil tablets are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase–producing strains), Moraxella catarrhalis (including β-lactamase–producing strains), or Streptococcus pyogenes . 1.3 Acute Bacterial Maxillary Sinusitis Cefuroxime axetil tablets are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute bacterial maxillary sinusitis caused by susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae (non -β -lactamase–producing strains only). Limitations of Use The effectiveness of Cefuroxime axetil for sinus infections caused by β-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis in patients with acute bacterial maxillary sinusitis was not established due to insufficient numbers of these isolates in the clinical trials [see Clinical Studies ( 14.1 )] . 1.4 Acute Bacterial Exacerbations of Chronic Bronchitis Cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (aged 13 and older) with mild-to-moderate acute bacterial exacerbations of chronic bronchitis caused by susceptible strains of Streptococcus pneumoniae , Haemophilus influenzae (β-lactamase–negative strains), or Haemophilus parainfluenzae (β-lactamase–negative strains). 1.5 Uncomplicated Skin and Skin-Structure Infections Cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (aged 13 and older) with uncomplicated skin and skin-structure infections caused by susceptible strains of Staphylococcus aureus (including β - lactamase–producing strains) or Streptococcus pyogenes. 1.6 Uncomplicated Urinary Tract Infections Cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (aged 13 and older) with uncomplicated urinary tract infections caused by susceptible strains of Escherichia coli or Klebsiella pneumoniae . 1.7 Uncomplicated Gonorrhea Cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (aged 13 and older) with uncomplicated gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing susceptible strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing susceptible strains of Neisseria gonorrhoeae . 1.8 Early Lyme Disease (erythema migrans) Cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (aged 13 and older) with early Lyme disease (erythema migrans) caused by susceptible strains of Borrelia burgdorferi. 1.10 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Serious hypersensitivity (anaphylactic) reactions: In the event of a serious reaction, discontinue cefuroxime axetil and institute appropriate therapy. ( 5.1 ) Clostridioides difficile -associated diarrhea (CDAD): If diarrhea occurs, evaluate patients for CDAD. ( 5.2 ) 5.1 Anaphylactic Reactions Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on β-lactam antibacterials, including cefuroxime axetil [see Adverse Reactions ( 6.2 )] . These reactions are more likely to occur in individuals with a history of β-lactam hypersensitivity and/or a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins. Cefuroxime axetil is contraindicated in patients with a known hypersensitivity to cefuroxime axetil or other β-lactam antibacterial drugs [see Contraindications ( 4 )] . Before initiating therapy with cefuroxime axetil, inquire about previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens. If an allergic reaction occurs, discontinue cefuroxime axetil and institute appropriate therapy. 5.2 Clostridioides difficile -Associated Diarrhea Clostridioides difficile- associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefuroxime axetil, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. 5.3 Potential for Microbial Overgrowth The possibility of superinfections with fungal or bacterial pathogens should be considered during therapy. 5.4 Development of Drug-Resistant Bacteria Prescribing cefuroxime axetil either in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. 5.6 Interference with Glucose Tests A false-positive result for glucose in the urine may occur with copper reduction tests, and a false-negative result for blood/plasma glucose may occur with ferricyanide tests in subjects receiving cefuroxime axetil [see Drug Interactions ( 7.3) ] ."],"clinical_studies_table":["
U.S. Subjectsa South American Subjectsb
Cefuro xime Axetil Tablets 250 mg Twice Daily (n = 49) Control c (n = 43) Cefuroxime Axetil Tablets 250 mg Twice Daily (n = 49) Controlc (n = 43)
Clinical success (cure + improvement) 65% 53% 77% 74%
Clinical cure 53% 44% 72% 64%
Clinical improvement 12% 9% 5% 10%
","
Part I (1 Month after 20 Days of Treatment)a Part II (1 Year after 20 Days of Treatment)b
Cefuroxime Axetil Tablets 500 mg Twice Daily (n = 125) Doxycycline 100 mg 3 Times Daily (n = 108) Cefuroxime Axetil Tablets 500 mg Twice Daily (n = 105c) Doxycycline 100 mg 3 Times Daily (n = 83c)
Satisfactory clinical outcomed 91% 93% 84% 87%
Clinical cure/success 72% 73% 73% 73%
Clinical improvement 19% 19% 10% 13%
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Although lifetime studies in animals have not been performed to evaluate carcinogenic potential, no mutagenic activity was found for cefuroxime axetil in a battery of bacterial mutation tests. Positive results were obtained in an in vitro chromosome aberration assay; however, negative results were found in an in vivo micronucleus test at doses up to 1.5 g/kg. Fertility studies in rats (males dosed for 70 days prior to and through mating; females dosed 21 days prior to mating through lactation) at doses up to 1,000 mg/kg/day (9 times the MRHD based on body surface area) have revealed no adverse effects on fertility."],"pharmacokinetics_table":["
Doseb (Cefuroxime Equivalent) Peak Plasma Concentration (mcg/mL) Time of Peak Plasma Concentration (h) Mean Elimination Half-life (h) AUC (mcg•h/mL)
125 mg 2.1 2.2 1.2 6.7
250 mg 4.1 2.5 1.2 12.9
500 mg 7 3 1.2 27.4
1,000 mg 13.6 2.5 1.3 50
"],"adverse_reactions_table":["
Adverse Reaction Cefuroxime Axetil (n = 912)
Blood and lymphatic system disorders
Eosinophilia 1%
Gastrointestinal disorders
Diarrhea 4%
Nausea/Vomiting 3%
Investigations
Transient elevation in AST 2%
Transient elevation in ALT 2%
Transient elevation in LDH 1%
","
Adverse Reaction Cefuroxime axetil (n = 1,061)
Gastrointestinal disorders
Nausea/Vomiting 7%
Diarrhea 4%
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Allergic Reactions Inform patients that cefuroxime axetil is a cephalosporin that can cause allergic reactions in some individuals [see Warnings and Precautions ( 5.1 )] . Clostridioides difficile - Associated Diarrhea Inform patients that diarrhea is a common problem caused by antibacterials, and it usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken their last dose of the antibacterial. If this occurs, advise patients to contact their physician as soon as possible. Crushing Tablets Instruct patients to swallow the tablet whole, without crushing the tablet. Patients who cannot swallow the tablet whole should receive the oral suspension. Drug Resistance Inform patients that antibacterial drugs, including cefuroxime axetil, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When cefuroxime axetil is prescribed to treat a bacterial infection, inform patients that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefuroxime axetil or other antibacterial drugs in the future. Alkem Laboratories Ltd., INDIA. Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 Revised: November, 2021 PT 0996-08"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Tablets and oral suspension are not bioequivalent and are therefore not substitutable on a milligram-per-milligram basis. ( 2.1 ) Administer tablets with or without food. ( 2.2 ) Administer cefuroxime axetil tablets as described in the dosage guidelines. ( 2.2 ) Dosage adjustment is required for patients with impaired renal function. ( 2.5 ) Adult Patients and Pediatric Patients Dosage Guidelines for Cefuroxime Axetil Tablets Infection Dosage Duration (Days) Adults and Adolescents (13 years and older) Pharyngitis/tonsillitis (mild to moderate) 250 mg every 12 hours 10 Acute bacterial maxillary sinusitis (mild to moderate) 250 mg every 12 hours 10 Acute bacterial exacerbations of chronic bronchitis (mild to moderate) 250 or 500 mg every 12 hours 10 Uncomplicated skin and skin-structure infections 250 or 500 mg every 12 hours 10 Uncomplicated urinary tract infections 250 mg every 12 hours 7 to 10 Uncomplicated gonorrhea 1,000 mg single dose Early Lyme disease 500 mg every 12 hours 20 Pediatric Patients younger than 13 years (who can swallow tablets whole ) Acute bacterial otitis media 250 mg every 12 hours 10 Acute bacterial maxillary sinusitis 250 mg every 12 hours 10 2.1 Important Administration Instructions Cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bioequivalent and are therefore not substitutable on a milligram-per-milligram basis [see Clinical Pharmacology ( 12.3 )]. Administer cefuroxime axetil tablets as described in the appropriate dosage guidelines [see Dosage and Administration ( 2.2 )]. Administer cefuroxime axetil tablets with or without food. Pediatric patients (aged 13 years and older) who cannot swallow the cefuroxime axetil tablets whole should receive cefuroxime axetil for oral suspension because the tablet has a strong, persistent bitter taste when crushed [see Dosage and Administration ( 2.2 )]. 2.2 Dosage for Cefuroxime axetil Tablets Administer cefuroxime axetil tablets as described in the dosage guidelines table below with or without food. Table 1. Adult Patients and Pediatric Patients Dosage Guidelines for Cefuroxime Axetil Tablets Infection Dosage Duration (Days) Adults and Adolescents (13 years and older) Pharyngitis/tonsillitis (mild to moderate) 250 mg every 12 hours 10 Acute bacterial maxillary sinusitis (mild to moderate) 250 mg every 12 hours 10 Acute bacterial exacerbations of chronic bronchitis(mild to moderate ) 250 or 500 mg every 12 hours 10a Uncomplicated skin and skin-structure infections 250 or 500 mg every 12 hours 10 Uncomplicated urinary tract infections 250 mg every 12 hours 7 to 10 Uncomplicated gonorrhea 1,000 mg single dose Early Lyme disease 500 mg every 12 hours 20 Pediatric Patients younger than 13 years (who can swallow tablets whole) b Acute bacterial otitis media 250 mg every 12 hours 10 Acute bacterial maxillary sinusitis 250 mg every 12 hours 10 a The safety and effectiveness of cefuroxime axetil administered for less than 10 days in patients with acute exacerbations of chronic bronchitis have not been established. b When crushed, the tablet has a strong, persistent bitter taste. Therefore, patients who cannot swallow the tablet whole should receive the oral suspension. 2.5 Dosage in Patients with Impaired Renal Function A dosage interval adjustment is required for patients whose creatinine clearance is less than 30 mL/min, as listed in Table 4 below, because cefuroxime is eliminated primarily by the kidney [see Clinical Pharmacology ( 12.3 )]. Table 4. Dosing in Adults with Renal Impairment Creatinine Clearance (mL/min) Recommended Dosage ≥30 No dosage adjustment 10 to ˂30 Standard individual dose given every 24 hours ˂10 (without hemodialysis) Standard individual dose given every 48 hours Hemodialysis A single additional standard dose should be given at the end of each dialysis"],"spl_product_data_elements":["Cefuroxime axetil Cefuroxime axetil CEFUROXIME AXETIL CEFUROXIME MICROCRYSTALLINE CELLULOSE CROSCARMELLOSE SODIUM SODIUM LAURYL SULFATE SILICON DIOXIDE CALCIUM STEARATE CALCIUM CARBONATE CROSPOVIDONE (120 .MU.M) HYPROMELLOSE 2910 (6 MPA.S) TITANIUM DIOXIDE PROPYLENE GLYCOL FD&C BLUE NO. 1 ALUMINUM OXIDE 204 cefuroxime-structure cefuroxime-alkem-logo"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Cefuroxime axetil tablets,USP 250 mg of cefuroxime (as cefuroxime axetil), are blue, capsule-shaped, biconvex, film-coated tablets with “204” debossed on one side and plain on the other side. Cefuroxime Axetil Tablets,USP 500 mg of cefuroxime (as cefuroxime axetil), are blue, capsule-shaped, biconvex, film-coated tablets with 203” debossed on one side and plain on the other side. Tablets: 250 mg and 500 mg"],"clinical_pharmacology_table":["
Doseb (Cefuroxime Equivalent) Peak Plasma Concentration (mcg/mL) Time of Peak Plasma Concentration (h) Mean Elimination Half-life (h) AUC (mcg•h/mL)
125 mg 2.1 2.2 1.2 6.7
250 mg 4.1 2.5 1.2 12.9
500 mg 7 3 1.2 27.4
1,000 mg 13.6 2.5 1.3 50
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Available data from published epidemiologic studies, case series, and case reports over several decades with cephalosporin use, including cefuroxime axetil, in pregnant women have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data) . In studies in pregnant mice and rats administered oral cefuroxime axetil during organogenesis at 14 and 9 times the maximum recommended human dose (MRHD) based on body surface area, respectively, there were no adverse developmental outcomes (see Data). The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk: Maternal gonorrhea may be associated with preterm birth, low neonatal birth weight, chorioamnionitis, intrauterine growth restriction, small for gestational age, and premature rupture of membranes. Perinatal transmission of gonorrhea to the offspring can result in infant blindness, joint infections, and bloodstream infections. Data Human Data: While available studies cannot definitively establish the absence of risk, published data from epidemiologic studies, case series, and case reports over several decades have not identified an association with cephalosporin use (including cefuroxime axetil) during pregnancy and major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Available studies have methodologic limitations, including small sample size, retrospective data collection, and inconsistent comparator groups. Animal Data: Studies performed with oral cefuroxime axetil administered to pregnant mice during organogenesis (Gestation Days 7 through 16) at doses up to 3,200 mg/kg/day (14 times the MRHD based on body surface area); and in rats dosed during organogenesis and lactation (Gestation Days 7 through 16 and Gestation Days 17 through Lactation Day 21, respectively) at doses up to 1,000 mg/kg/day (9 times the MRHD based on body surface area) have revealed no adverse developmental outcomes. 8.2 Lactation Risk Summary Based on several published case reports describing multiple lactating women who received cefuroxime via intravenous, intramuscular, and oral routes, cefuroxime is present in human milk. The highest maternal milk concentration described occurred in lactating women 8 hours after an intramuscular administration of cefuroxime 750 mg. Allowing for an infant milk consumption of 150 mL/kg/day, the estimated breastfed infant dose would be less than 1% of the adult dose . No data are available on the effects of the drug on the breastfed infant or the effects of the drug on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for cefuroxime and any potential adverse effects on the breastfed infant from cefuroxime or from the underlying maternal condition. 8.4 Pediatric Use The safety and effectiveness of cefuroxime axetil have been established for pediatric patients aged 3 months to 12 years for acute bacterial maxillary sinusitis based upon its approval in adults. Use of cefuroxime axetil in pediatric patients is supported by pharmacokinetic and safety data in adults and pediatric patients, and by clinical and microbiological data from adequate and well-controlled trials of the treatment of acute bacterial maxillary sinusitis in adults and of acute otitis media with effusion in pediatric patients. It is also supported by postmarketing adverse events surveillance. [See Indications and Usage ( 1 ), Dosage and Administration ( 2 ), Adverse Reactions (6), Clinical Pharmacology ( 12.3 ).] 8.5 Geriatric Use Of the total number of subjects who received cefuroxime axetil in 20 clinical trials, 375 were aged 65 and older while 151 were aged 75 and older. No overall differences in safety or effectiveness were observed between these subjects and younger adult subjects. Reported clinical experience has not identified differences in responses between the elderly and younger adult patients, but greater sensitivity of some older individuals cannot be ruled out. Cefuroxime is substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. 8.6 Renal Impairment Reducing the dosage of cefuroxime axetil is recommended for adult patients with severe renal impairment (creatinine clearance <30 mL/min) [see Dosage and Administration ( 2.5 ), Clinical Pharmacology ( 12.3 )] ."],"dosage_and_administration_table":["
Adult Patients and Pediatric Patients Dosage Guidelines for Cefuroxime Axetil Tablets
Infection Dosage Duration (Days)
Adults and Adolescents (13 years and older)
Pharyngitis/tonsillitis (mild to moderate) 250 mg every 12 hours 10
Acute bacterial maxillary sinusitis (mild to moderate) 250 mg every 12 hours 10
Acute bacterial exacerbations of chronic bronchitis (mild to moderate) 250 or 500 mg every 12 hours 10
Uncomplicated skin and skin-structure infections 250 or 500 mg every 12 hours 10
Uncomplicated urinary tract infections 250 mg every 12 hours 7 to 10
Uncomplicated gonorrhea 1,000 mg single dose
Early Lyme disease 500 mg every 12 hours 20
Pediatric Patients younger than 13 years (who can swallow tablets whole)
Acute bacterial otitis media 250 mg every 12 hours 10
Acute bacterial maxillary sinusitis 250 mg every 12 hours 10
","
Infection Dosage Duration (Days)
Adults and Adolescents (13 years and older)
Pharyngitis/tonsillitis (mild to moderate) 250 mg every 12 hours 10
Acute bacterial maxillary sinusitis (mild to moderate) 250 mg every 12 hours 10
Acute bacterial exacerbations of chronic bronchitis(mild to moderate ) 250 or 500 mg every 12 hours 10a
Uncomplicated skin and skin-structure infections 250 or 500 mg every 12 hours 10
Uncomplicated urinary tract infections 250 mg every 12 hours 7 to 10
Uncomplicated gonorrhea 1,000 mg single dose
Early Lyme disease 500 mg every 12 hours 20
Pediatric Patients younger than 13 years (who can swallow tablets whole) b
Acute bacterial otitis media 250 mg every 12 hours 10
Acute bacterial maxillary sinusitis 250 mg every 12 hours 10
","
Creatinine Clearance (mL/min) Recommended Dosage
≥30 No dosage adjustment
10 to ˂30 Standard individual dose given every 24 hours
˂10 (without hemodialysis) Standard individual dose given every 48 hours
Hemodialysis A single additional standard dose should be given at the end of each dialysis
"],"package_label_principal_display_panel":["Cefuroxime Axetil Tabs 250mg #20 Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Although lifetime studies in animals have not been performed to evaluate carcinogenic potential, no mutagenic activity was found for cefuroxime axetil in a battery of bacterial mutation tests. Positive results were obtained in an in vitro chromosome aberration assay; however, negative results were found in an in vivo micronucleus test at doses up to 1.5 g/kg. Fertility studies in rats (males dosed for 70 days prior to and through mating; females dosed 21 days prior to mating through lactation) at doses up to 1,000 mg/kg/day (9 times the MRHD based on body surface area) have revealed no adverse effects on fertility."]},"tags":[{"label":"Cephalosporin Antibacterial","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Carbonic anhydrase 2","category":"target"},{"label":"CA2","category":"gene"},{"label":"MMP9","category":"gene"},{"label":"MMP2","category":"gene"},{"label":"J01DC02","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Intramuscular","category":"route"},{"label":"Injection","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Acute bacterial sinusitis","category":"indication"},{"label":"Acute exacerbation of chronic bronchitis","category":"indication"},{"label":"Acute gonococcal cervicitis","category":"indication"},{"label":"Acute gonococcal endometritis","category":"indication"},{"label":"Acute gonococcal urethritis","category":"indication"},{"label":"Acute maxillary sinusitis","category":"indication"},{"label":"Glaxosmithkline","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"1006 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"925 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"923 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"840 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"826 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"782 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"761 reports"},{"date":"","signal":"ANXIETY","source":"FDA FAERS","actionTaken":"690 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"679 reports"},{"date":"","signal":"CHRONIC KIDNEY DISEASE","source":"FDA FAERS","actionTaken":"678 reports"}],"drugInteractions":[{"url":"/drug/esomeprazole","drug":"esomeprazole","action":"Monitor closely","effect":"May interact with Esomeprazole","source":"DrugCentral","drugSlug":"esomeprazole"},{"url":"/drug/lansoprazole","drug":"lansoprazole","action":"Monitor closely","effect":"May interact with Lansoprazole","source":"DrugCentral","drugSlug":"lansoprazole"},{"url":"/drug/omeprazole","drug":"omeprazole","action":"Monitor closely","effect":"May interact with Omeprazole","source":"DrugCentral","drugSlug":"omeprazole"},{"url":"/drug/pantoprazole","drug":"pantoprazole","action":"Monitor closely","effect":"May interact with Pantoprazole","source":"DrugCentral","drugSlug":"pantoprazole"},{"url":"/drug/rabeprazole","drug":"rabeprazole","action":"Monitor closely","effect":"May interact with Rabeprazole","source":"DrugCentral","drugSlug":"rabeprazole"}],"commonSideEffects":[{"effect":"Thrombophlebitis","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Diarrhea","drugRate":"1 in 220","severity":"common","_validated":true},{"effect":"Nausea","drugRate":"1 in 440","severity":"common","_validated":true},{"effect":"Rash","drugRate":"1 in 125","severity":"common","_validated":true},{"effect":"Transient eosinophilia","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Transient neutropenia","drugRate":"reported","severity":"unknown"},{"effect":"Leukopenia","drugRate":"1 in 750","severity":"mild","_validated":true},{"effect":"Thrombocytopenia","drugRate":"reported","severity":"unknown"},{"effect":"Transient rise in SGOT","drugRate":"1 in 25","severity":"mild","_validated":true},{"effect":"Transient rise in SGPT","drugRate":"1 in 25","severity":"mild","_validated":true},{"effect":"Alkaline phosphatase","drugRate":"1 in 50","severity":"mild","_validated":true},{"effect":"Bilirubin","drugRate":"1 in 500","severity":"mild","_validated":true},{"effect":"Elevations in serum creatinine","drugRate":"reported","severity":"unknown"},{"effect":"Decreased creatinine clearance","drugRate":"reported","severity":"unknown"},{"effect":"Cutaneous vasculitis","drugRate":"reported","severity":"unknown"},{"effect":"Seizure","drugRate":"reported","severity":"unknown"},{"effect":"Angioedema","drugRate":"reported","severity":"unknown"},{"effect":"Vomiting","drugRate":"reported","severity":"unknown"},{"effect":"Abdominal pain","drugRate":"reported","severity":"unknown"},{"effect":"Colitis","drugRate":"reported","severity":"unknown"},{"effect":"Vaginitis","drugRate":"reported","severity":"unknown"},{"effect":"Toxic nephropathy","drugRate":"reported","severity":"unknown"},{"effect":"Hepatic dysfunction","drugRate":"reported","severity":"unknown"},{"effect":"Aplastic anemia","drugRate":"reported","severity":"unknown"},{"effect":"Hemolytic anemia","drugRate":"reported","severity":"unknown"},{"effect":"Hemorrhage","drugRate":"reported","severity":"unknown"},{"effect":"Prolonged prothrombin time","drugRate":"reported","severity":"unknown"},{"effect":"Pancytopenia","drugRate":"reported","severity":"unknown"},{"effect":"Agranulocytosis","drugRate":"reported","severity":"unknown"}],"contraindications":["Blood coagulation disorder","Disease of liver","Factor II deficiency","Kidney disease","Pseudomembranous enterocolitis"],"specialPopulations":{"Pregnancy":"There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always","Geriatric use":"Of the 1,914 subjects who received cefuroxime in 24 clinical studies of cefuroxime, 901 (47%) were 65 years and older while 421 (22%) were 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater susceptibility of some older individuals to drug effects cannot be ruled out.","Paediatric use":"Safety and effectiveness in pediatric patients below months of age have not been established. Accumulation of other members of the cephalosporin class in newborn infants (with resulting prolongation of drug half-life) has been reported."}},"trials":[],"aliases":[],"company":"GSK","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CEFUROXIME","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:38:49.098320+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:39:00.580920+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:38:47.697525+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEFUROXIME","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:39:01.250217+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:38:46.070080+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:38:46.070092+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:39:02.806325+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Bacterial penicillin-binding protein inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:39:01.807984+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2146124/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:39:01.704990+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA065496","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:38:46.070094+00:00"}},"allNames":"zinacef","offLabel":[],"synonyms":["cefuroxime","biofuroxim","cefaloxime","cefasyn","cefuroxim","cefuroxime acid","cephuroxime","cefuroxime sodium","cefuroxime sodium salt"],"timeline":[{"date":"1983-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from COVIS INJECTABLES to Glaxosmithkline"},{"date":"1983-10-19","type":"positive","source":"DrugCentral","milestone":"FDA approval (Covis Injectables)"},{"date":"1987-12-28","type":"positive","source":"FDA Orange Book","milestone":"Ceftin approved — EQ 125MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"2003-04-25","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 3 manufacturers approved"}],"aiSummary":"Zinacef (Cefuroxime) is a cephalosporin antibacterial drug developed by Covis Injectables and currently owned by GlaxoSmithKline. It targets carbonic anhydrase 2 and is a small molecule modality. Approved in 1983, it is used to treat various bacterial infections, including acute sinusitis, bronchitis, and gonococcal infections. As an off-patent drug, it is available from multiple generic manufacturers. Key safety considerations include its short half-life and moderate bioavailability.","approvals":[{"date":"1983-10-19","orphan":false,"company":"COVIS INJECTABLES","regulator":"FDA"}],"brandName":"Zinacef","ecosystem":[{"indication":"Acute bacterial sinusitis","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azithromycin","slug":"azithromycin","company":""}],"globalPrevalence":null},{"indication":"Acute exacerbation of chronic bronchitis","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azithromycin","slug":"azithromycin","company":""},{"name":"cefditoren pivoxil","slug":"cefditoren-pivoxil","company":"Vansen Pharma"}],"globalPrevalence":null},{"indication":"Acute gonococcal cervicitis","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azithromycin","slug":"azithromycin","company":""}],"globalPrevalence":null},{"indication":"Acute gonococcal endometritis","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"cefotetan","slug":"cefotetan","company":""},{"name":"cefoxitin","slug":"cefoxitin","company":""}],"globalPrevalence":null},{"indication":"Acute gonococcal urethritis","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azithromycin","slug":"azithromycin","company":""}],"globalPrevalence":null},{"indication":"Acute maxillary sinusitis","otherDrugs":[{"name":"cefpodoxime proxetil","slug":"cefpodoxime-proxetil","company":""},{"name":"cefuroxime axetil","slug":"cefuroxime-axetil","company":"Glaxosmithkline"},{"name":"ciprofloxacin","slug":"ciprofloxacin","company":"Bayer Hlthcare"},{"name":"clarithromycin","slug":"clarithromycin","company":"Abbvie"}],"globalPrevalence":null},{"indication":"Acute otitis media","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"benzylpenicillin","slug":"benzylpenicillin","company":"Pfizer"},{"name":"cefalexin","slug":"cefalexin","company":"Shionogi Inc"}],"globalPrevalence":null},{"indication":"Bacterial infection due to Klebsiella pneumoniae","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"azlocillin","slug":"azlocillin","company":"Bayer Pharmaceuticals Corp"},{"name":"aztreonam","slug":"aztreonam","company":"Bristol Myers Squibb"}],"globalPrevalence":null}],"mechanism":{"target":"Carbonic anhydrase 2","novelty":"Follow-on","targets":[{"gene":"CA2","source":"DrugCentral","target":"Carbonic anhydrase 2","protein":"Carbonic anhydrase 2"},{"gene":"MMP9","source":"DrugCentral","target":"Matrix metalloproteinase-9","protein":"Matrix metalloproteinase-9"},{"gene":"MMP2","source":"DrugCentral","target":"72 kDa type IV collagenase","protein":"72 kDa type IV collagenase"}],"modality":"Small Molecule","drugClass":"Cephalosporin Antibacterial","explanation":"Mechanismof Action:. Cefuroxime is bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefuroxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria.","oneSentence":"Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.","technicalDetail":"Cefuroxime exerts its antibacterial effect by binding to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, resulting in the inhibition of cell wall synthesis and ultimately leading to bacterial cell lysis.","_target_confidence":0.5},"commercial":{"launchDate":"1983","_launchSource":"DrugCentral (FDA 1983-10-19, COVIS INJECTABLES)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/565","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CEFUROXIME","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEFUROXIME","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T09:31:12.427236","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:39:07.770308+00:00","fieldsConflicting":3,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"cefoxitin","drugSlug":"cefoxitin","fdaApproval":"1978-10-18","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefaclor","drugSlug":"cefaclor","fdaApproval":"1979-04-04","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefotetan","drugSlug":"cefotetan","fdaApproval":"1985-12-27","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefonicid","drugSlug":"cefonicid","fdaApproval":"","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefotiam","drugSlug":"cefotiam","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"loracarbef","drugSlug":"loracarbef","fdaApproval":"1991-12-31","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"cefmetazole","drugSlug":"cefmetazole","fdaApproval":"1989-12-11","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"cefprozil","drugSlug":"cefprozil","fdaApproval":"1991-12-23","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ceforanide","drugSlug":"ceforanide","fdaApproval":"1984-05-24","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"cefuroxime","indications":{"approved":[{"name":"Acute bacterial sinusitis","source":"DrugCentral","snomedId":75498004,"regulator":"FDA","eligibility":null},{"name":"Acute exacerbation of chronic bronchitis","source":"DrugCentral","snomedId":425748003,"regulator":"FDA","eligibility":null},{"name":"Acute gonococcal cervicitis","source":"DrugCentral","snomedId":20943002,"regulator":"FDA","eligibility":null},{"name":"Acute gonococcal endometritis","source":"DrugCentral","snomedId":65295003,"regulator":"FDA","eligibility":null},{"name":"Acute gonococcal urethritis","source":"DrugCentral","snomedId":29864006,"regulator":"FDA","eligibility":null},{"name":"Acute maxillary sinusitis","source":"DrugCentral","snomedId":68272006,"regulator":"FDA","eligibility":null},{"name":"Acute otitis media","source":"DrugCentral","snomedId":3110003,"regulator":"FDA","eligibility":null},{"name":"Bacterial infection due to Klebsiella pneumoniae","source":"DrugCentral","snomedId":186435004,"regulator":"FDA","eligibility":null},{"name":"Bacterial meningitis","source":"DrugCentral","snomedId":95883001,"regulator":"FDA","eligibility":null},{"name":"Bacterial pneumonia","source":"DrugCentral","snomedId":53084003,"regulator":"FDA","eligibility":null},{"name":"Bacterial septicemia","source":"DrugCentral","snomedId":10001005,"regulator":"FDA"},{"name":"Bacterial urinary infection","source":"DrugCentral","snomedId":312124009,"regulator":"FDA"},{"name":"Disseminated Gonococcal Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Escherichia coli urinary tract infection","source":"DrugCentral","snomedId":301011002,"regulator":"FDA"},{"name":"Gonorrhea","source":"DrugCentral","snomedId":15628003,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Gonorrhea of pharynx","source":"DrugCentral","snomedId":74372003,"regulator":"FDA"},{"name":"Gonorrhea of rectum","source":"DrugCentral","snomedId":42746002,"regulator":"FDA"},{"name":"H. Influenzae Meningitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Haemophilus Influenzae Acute Otitis Media","source":"DrugCentral","snomedId":19021002,"regulator":"FDA"},{"name":"Haemophilus Influenzae Bronchitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Haemophilus Influenzae Chronic Bronchitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Haemophilus Parainfluenzae Bronchitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Haemophilus Parainfluenzae Chronic Bronchitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Haemophilus Septicemia","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Haemophilus influenzae pneumonia","source":"DrugCentral","snomedId":70036007,"regulator":"FDA"},{"name":"Impetigo","source":"DrugCentral","snomedId":48277006,"regulator":"FDA"},{"name":"Infection due to Enterobacteriaceae","source":"DrugCentral","snomedId":128945009,"regulator":"FDA"},{"name":"Infection due to Escherichia coli","source":"DrugCentral","snomedId":71057007,"regulator":"FDA"},{"name":"Infection due to Staphylococcus aureus","source":"DrugCentral","snomedId":406602003,"regulator":"FDA"},{"name":"Infection of bone","source":"DrugCentral","snomedId":111253001,"regulator":"FDA"},{"name":"Infection of skin AND/OR subcutaneous tissue","source":"DrugCentral","snomedId":19824006,"regulator":"FDA"},{"name":"Infectious disorder of joint","source":"DrugCentral","snomedId":363162000,"regulator":"FDA"},{"name":"Infective otitis media","source":"DrugCentral","snomedId":312218008,"regulator":"FDA"},{"name":"Klebsiella cystitis","source":"DrugCentral","snomedId":60867007,"regulator":"FDA"},{"name":"Lower respiratory tract infection","source":"DrugCentral","snomedId":50417007,"regulator":"FDA"},{"name":"Lyme disease","source":"DrugCentral","snomedId":23502006,"regulator":"FDA"},{"name":"Moraxella Catarrhalis Acute Otitis Media","source":"DrugCentral","snomedId":703469002,"regulator":"FDA","globalPrevalence":709000000,"prevalenceMethod":"ai-extracted","prevalenceSource":"Influenza Other Respir Viruses, 2026 (PMID:41640273)"},{"name":"Open Heart Surgery Infection Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Osteomyelitis due to Staphylococcus aureus","source":"DrugCentral","snomedId":428783003,"regulator":"FDA"},{"name":"Pneumonia due to Escherichia coli","source":"DrugCentral","snomedId":51530003,"regulator":"FDA"},{"name":"Pneumonia due to Streptococcus","source":"DrugCentral","snomedId":34020007,"regulator":"FDA"},{"name":"Prevention of Perioperative Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Rhinoscleroma","source":"DrugCentral","snomedId":72409005,"regulator":"FDA"},{"name":"Septicemia due to Escherichia coli","source":"DrugCentral","snomedId":9323009,"regulator":"FDA"},{"name":"Staphylococcal meningitis","source":"DrugCentral","snomedId":12166008,"regulator":"FDA"},{"name":"Staphylococcal pneumonia","source":"DrugCentral","snomedId":22754005,"regulator":"FDA"},{"name":"Staphylococcal septicemia","source":"DrugCentral","snomedId":111821004,"regulator":"FDA"},{"name":"Staphylococcus Aureus Joint Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Streptococcal meningitis","source":"DrugCentral","snomedId":4510004,"regulator":"FDA"},{"name":"Streptococcal septicemia","source":"DrugCentral","snomedId":29577008,"regulator":"FDA"},{"name":"Streptococcal tonsillitis","source":"DrugCentral","snomedId":41582007,"regulator":"FDA"},{"name":"Streptococcus Pneumoniae Bronchitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Streptococcus Pneumoniae Chronic Bronchitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Streptococcus pyogenes infection","source":"DrugCentral","snomedId":302809008,"regulator":"FDA"}],"offLabel":[{"name":"Neonatal meningitis","source":"DrugCentral","drugName":"CEFUROXIME","evidenceCount":34,"evidenceLevel":"moderate"},{"name":"Neonatal pneumonia","source":"DrugCentral","drugName":"CEFUROXIME","evidenceCount":75,"evidenceLevel":"strong"},{"name":"Pyrexia of unknown origin","source":"DrugCentral","drugName":"CEFUROXIME","evidenceCount":8,"evidenceLevel":"emerging"},{"name":"Sepsis of the newborn","source":"DrugCentral","drugName":"CEFUROXIME","evidenceCount":39,"evidenceLevel":"moderate"}],"pipeline":[]},"currentOwner":"Glaxosmithkline","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"cefoxitin","brandName":"cefoxitin","genericName":"cefoxitin","approvalYear":"1978","relationship":"same-class"},{"drugId":"cefaclor","brandName":"cefaclor","genericName":"cefaclor","approvalYear":"1979","relationship":"same-class"},{"drugId":"cefotetan","brandName":"cefotetan","genericName":"cefotetan","approvalYear":"1985","relationship":"same-class"},{"drugId":"cefonicid","brandName":"cefonicid","genericName":"cefonicid","approvalYear":"","relationship":"same-class"},{"drugId":"cefotiam","brandName":"cefotiam","genericName":"cefotiam","approvalYear":"","relationship":"same-class"},{"drugId":"loracarbef","brandName":"loracarbef","genericName":"loracarbef","approvalYear":"1991","relationship":"same-class"},{"drugId":"cefmetazole","brandName":"cefmetazole","genericName":"cefmetazole","approvalYear":"1989","relationship":"same-class"},{"drugId":"cefprozil","brandName":"cefprozil","genericName":"cefprozil","approvalYear":"1991","relationship":"same-class"},{"drugId":"ceforanide","brandName":"ceforanide","genericName":"ceforanide","approvalYear":"1984","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07033039","phase":"NA","title":"Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre","status":"RECRUITING","sponsor":"University of Nove de Julho","startDate":"2026-01-30","conditions":["Rhinoplasty","Edema"],"enrollment":60,"completionDate":"2030-11-30"},{"nctId":"NCT06406114","phase":"PHASE2","title":"Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-05-05","conditions":["Drug Allergy","Cephalosporin Allergy","Drug Hypersensitivity","Antibiotic Allergy","Beta Lactam Adverse Reaction","Drug-Induced Anaphylaxis","Cephalosporin Reaction"],"enrollment":300,"completionDate":"2028-12-31"},{"nctId":"NCT05750966","phase":"NA","title":"Short-course Antibiotics vs Standard Course Antibiotics in Patients With Cholangitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2023-07-19","conditions":["Cholangitis"],"enrollment":440,"completionDate":"2026-09-01"},{"nctId":"NCT07267013","phase":"PHASE2","title":"Clindamycin as an Alternative to Vancomycin in Patients Undergoing Aortic Cardiac Surgery With Extracorporeal Circulation (ECC)","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-03-30","conditions":["Aortic Surgery","Extracorporeal Circulation"],"enrollment":25,"completionDate":"2026-10-30"},{"nctId":"NCT07346742","phase":"NA","title":"Prevention of Surgical Site Infection in Open Paediatric Groin Surgeries Using Intravenous Prophylactic Antibiotics and Antimicrobial-coated Sutures","status":"RECRUITING","sponsor":"Olawumi Olajide","startDate":"2025-03-09","conditions":["Inguinal Hernia","Hydroceles","Surgical Site Infection"],"enrollment":174,"completionDate":"2026-02-27"},{"nctId":"NCT07236944","phase":"PHASE4","title":"Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2025-12","conditions":["Febrile Urinary Tract Infection"],"enrollment":560,"completionDate":"2029-03"},{"nctId":"NCT06663527","phase":"NA","title":"Compound Phellodendron Decoction May Promote Wound Healing After Anal Fistulotomy","status":"COMPLETED","sponsor":"The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine","startDate":"2024-10-26","conditions":["Fistula in Ano"],"enrollment":60,"completionDate":"2025-02-01"},{"nctId":"NCT03935828","phase":"PHASE2","title":"Effect of Topical Sinonasal Antibiotics","status":"WITHDRAWN","sponsor":"United States Naval Medical Center, San Diego","startDate":"2019-06","conditions":["Chronic Rhinosinusitis (Diagnosis)","Antibiotic Side Effect"],"enrollment":0,"completionDate":"2021-06"},{"nctId":"NCT05157113","phase":"PHASE4","title":"Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2022-05-31","conditions":["Cataract","Surgery","Compliance, Patient","Compliance, Medication","Satisfaction, Patient"],"enrollment":70,"completionDate":"2026-06-01"},{"nctId":"NCT06849037","phase":"NA","title":"Comparing Infectious Morbidity Among Women With Meconium-stained Amniotic Fluid at Term, Between Those Treated With Prophylactic Antibiotics Zinacef vs. Placebo","status":"RECRUITING","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2025-02-18","conditions":["Meconium-stained Amniotic Fluid","Chorioamnionitis"],"enrollment":182,"completionDate":"2029-02-13"},{"nctId":"NCT05530174","phase":"NA","title":"Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With a Fracture","status":"ACTIVE_NOT_RECRUITING","sponsor":"Soren Overgaard","startDate":"2022-09-01","conditions":["Fracture of Hip","Total Hip Arthroplasty","Prosthetic-joint Infection","Fracture Acetabular"],"enrollment":2000,"completionDate":"2025-04-01"},{"nctId":"NCT05530551","phase":"NA","title":"Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With OA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Soren Overgaard","startDate":"2022-09-01","conditions":["Osteoarthritis, Hip","Total Hip Arthroplasty","Prosthetic-joint Infection"],"enrollment":20000,"completionDate":"2025-03-01"},{"nctId":"NCT06709196","phase":"PHASE4","title":"Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2025-01-07","conditions":["Cystectomy","Bladder Cancer Requiring Cystectomy","Postoperative Infections","Antibiotic Prophylaxis","Ileal Conduit"],"enrollment":248,"completionDate":"2027-01"},{"nctId":"NCT05502380","phase":"PHASE3","title":"Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery","status":"RECRUITING","sponsor":"Balgrist University Hospital","startDate":"2022-09-15","conditions":["Surgical Site Infection","Microbial Colonization","Antibiotic Resistant Infection"],"enrollment":1100,"completionDate":"2025-12-12"},{"nctId":"NCT05784311","phase":"PHASE4","title":"Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2023-03-06","conditions":["Pancreatic Cancer"],"enrollment":344,"completionDate":"2026-01"},{"nctId":"NCT06505135","phase":"PHASE1","title":"Stem Cell Treatment for Regeneration of the Rotator Cuff (Lipo-Cuff Study)","status":"ENROLLING_BY_INVITATION","sponsor":"University of Southern Denmark","startDate":"2024-09-03","conditions":["Rotator Cuff Tears","Rotator Cuff Injuries","Rotator Cuff Tear Arthropathy"],"enrollment":30,"completionDate":"2026-09"},{"nctId":"NCT04803422","phase":"NA","title":"Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis.","status":"COMPLETED","sponsor":"Zealand University Hospital","startDate":"2021-04-01","conditions":["Complicated Appendicitis"],"enrollment":3193,"completionDate":"2024-06-30"},{"nctId":"NCT06527560","phase":"PHASE4","title":"Clinical Trial Comparing Oral Versus Intravenous Cefuroxime in Pregnant Women with Pyelonephritis","status":"RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2024-09-09","conditions":["Pyelonephritis in Pregnancy"],"enrollment":100,"completionDate":"2027-12-31"},{"nctId":"NCT05337566","phase":"NA","title":"Does Additional Use of Preoperative Azithromycin Decrease Posthysterectomy Infections","status":"RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2022-09-05","conditions":["Infection Post Op","Hysterectomy","Antibiotics","Prophylactic"],"enrollment":2278,"completionDate":"2030-12"},{"nctId":"NCT04755179","phase":"","title":"Identification of the Optimal Treatment Strategy for Complex Appendicitis in the Pediatric Population","status":"COMPLETED","sponsor":"Ramon Gorter","startDate":"2019-08-12","conditions":["Appendicitis","Appendix Mass","Appendicitis Perforated"],"enrollment":1308,"completionDate":"2024-07-03"},{"nctId":"NCT05609240","phase":"PHASE2","title":"Colo-Pro_2: Bolus-continuous Infusion Cefuroxime Prophylaxis for the Prevention of Infections After Colorectal Surgery","status":"RECRUITING","sponsor":"University of Leeds","startDate":"2023-05-10","conditions":["Antibiotic Prophylaxis","Colorectal Surgery"],"enrollment":180,"completionDate":"2025-05-01"},{"nctId":"NCT06351891","phase":"PHASE4","title":"Efficacy and Safety of Bismuth Quadruple Therapy Containing Cefuroxime and Tetracycline as First-line Therapy for Eradicating Helicobacter Pylori in Patients Allergic to Penicillin","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-04","conditions":["Helicobacter Pylori Infection"],"enrollment":248,"completionDate":"2024-12"},{"nctId":"NCT02538991","phase":"NA","title":"TVT Versus Bulkamid®-Injections in Treatment of Stress Urinary Incontinence","status":"ACTIVE_NOT_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2015-09","conditions":["Urinary Stress Incontinence"],"enrollment":224,"completionDate":"2024-12"},{"nctId":"NCT04510558","phase":"NA","title":"Reducing the Incidence of Incisional Hernia After Stoma Closure Using a Prophylactic Mesh","status":"UNKNOWN","sponsor":"University Hospital, Geneva","startDate":"2021-05-01","conditions":["Incisional Hernia"],"enrollment":72,"completionDate":"2024-12"},{"nctId":"NCT01581047","phase":"","title":"Pharmacokinetics of Small Spectrum Beta-lactam Antibiotics (Amoxicillin/Clavulanic Acid and Cefuroxime) in Patients on Intensive Care Units","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2012-03-15","conditions":["Infection"],"enrollment":37,"completionDate":"2014-05-07"},{"nctId":"NCT04378868","phase":"PHASE4","title":"Role of Delay and Antibiotics on Perforation Rate While Waiting Appendectomy","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2020-05-18","conditions":["Appendicitis"],"enrollment":1800,"completionDate":"2023-02-23"},{"nctId":"NCT05398081","phase":"PHASE2","title":"Cefuroxime vs Ceftriaxone for SSI Prevention in Neurosurgery","status":"COMPLETED","sponsor":"Dr. Promise Tamunoipiriala Jaja","startDate":"2021-12-01","conditions":["Surgical Site Infection","Antibiotics Prophylaxis"],"enrollment":96,"completionDate":"2022-03-05"},{"nctId":"NCT02800785","phase":"NA","title":"The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-05","conditions":["Appendicitis"],"enrollment":1552,"completionDate":"2021-09-01"},{"nctId":"NCT04303390","phase":"PHASE4","title":"24 Vs 48 Hours of Cefazolin or Cefuroxime as Prophylaxis","status":"COMPLETED","sponsor":"Saud Al Babtain Cardiac Center","startDate":"2018-02-06","conditions":["Surgical Site Infection"],"enrollment":568,"completionDate":"2022-05-31"},{"nctId":"NCT03108690","phase":"PHASE4","title":"Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia","status":"WITHDRAWN","sponsor":"Sara Thønnings","startDate":"2017-10-01","conditions":["Bacteremia"],"enrollment":0,"completionDate":"2023-03-09"},{"nctId":"NCT05711810","phase":"PHASE4","title":"Medicine-induced Cardiac Hemodialysis on COVID-19","status":"COMPLETED","sponsor":"Yang I. Pachankis","startDate":"2023-01-02","conditions":["Severe Acute Respiratory Syndrome-related Coronavirus","Renal Dialysis","Vaccines","Myocarditis Allergic","Infection Viral"],"enrollment":1,"completionDate":"2023-01-12"},{"nctId":"NCT03877289","phase":"PHASE4","title":"Efficacy of Oxybutynin in Paediatric Cystitis","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2008-10","conditions":["Cystitis"],"enrollment":81,"completionDate":"2014-07"},{"nctId":"NCT04479657","phase":"EARLY_PHASE1","title":"Qingfei Granule for the Treatment of the Pediatric Acute Upper Respiratory Tract Infection With Bacterial Infection","status":"UNKNOWN","sponsor":"Zhong Wang","startDate":"2020-10-17","conditions":["Upper Respiratory Tract Infection","Bacterial Infection","Chinese Medicine","Pediatric Acute Upper Respiratory Tract Infection"],"enrollment":60,"completionDate":"2024-06"},{"nctId":"NCT04723472","phase":"NA","title":"Bismuth Quadruple Therapy With Cefuroxime for Helicobacter Pylori Eradication Treatment","status":"SUSPENDED","sponsor":"Shanghai East Hospital","startDate":"2023-08-01","conditions":["Helicobacter Pylori Infection"],"enrollment":82,"completionDate":"2025-12-31"},{"nctId":"NCT05606302","phase":"","title":"A Multi-center Clinical Study of Drug Antibody and Precision Transfusion in China","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2021-10-01","conditions":["Drug-specific Antibodies"],"enrollment":14000,"completionDate":"2023-12"},{"nctId":"NCT05577273","phase":"NA","title":"Does Antibiotic Prophylaxis at Urinary Catheter Removal Prevent Urinary Tract Infections","status":"UNKNOWN","sponsor":"Omri Schwarztuch Gildor","startDate":"2018-08-14","conditions":["Urologic Diseases","Urinary Tract Disease"],"enrollment":1000,"completionDate":"2023-08-31"},{"nctId":"NCT04470973","phase":"","title":"Pharmacokinetics of Amikacin and Cefuroxime in Critically Ill Patients.","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2020-07-15","conditions":["Sepsis","Septic Shock","Infection, Bacterial","Critically Ill"],"enrollment":40,"completionDate":"2023-12-15"},{"nctId":"NCT05388747","phase":"","title":"Population Pharmacokinetics, Effectiveness and Safety of Cefuroxime in Neonates","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2022-05-16","conditions":["Infectious Disease"],"enrollment":100,"completionDate":"2025-12-01"},{"nctId":"NCT04161599","phase":"PHASE4","title":"Preoperative Oral Antibiotics With vs Without Mechanical Bowel Preparation to Reduce Surgical Site Infections Following Colonic Resection: an International Randomized Controlled Trial.","status":"UNKNOWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2022-03-01","conditions":["Wounds and Injuries","Surgery--Complications"],"enrollment":968,"completionDate":"2024-07"},{"nctId":"NCT05200975","phase":"NA","title":"Target Attainment of Cefuroxim","status":"UNKNOWN","sponsor":"Noordwest Ziekenhuisgroep","startDate":"2022-01-15","conditions":["Infection, Bacterial","Kinesics"],"enrollment":45,"completionDate":"2023-01-01"},{"nctId":"NCT05293977","phase":"NA","title":"Short-Term Use of Antibiotics and Adherence Level","status":"COMPLETED","sponsor":"Jordan University of Science and Technology","startDate":"2020-08-03","conditions":["Acute Infection"],"enrollment":589,"completionDate":"2021-12-15"},{"nctId":"NCT04146142","phase":"NA","title":"Transperineal MRI-TRUS Fusion Guided Prostate Biopsy With vs Without Antibiotic Prophylaxis","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2019-11-11","conditions":["Prostate Biopsy","Antibiotic"],"enrollment":550,"completionDate":"2021-04-30"},{"nctId":"NCT00000752","phase":"PHASE2","title":"Preventing Frequent Sinus Infections in HIV-Infected Patients","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections","Sinusitis"],"enrollment":0,"completionDate":"1993-02"},{"nctId":"NCT02972944","phase":"NA","title":"Laparoscopic Cholecystectomy or Conservative Treatment in the Acute Cholecystitis of Elderly Patients","status":"UNKNOWN","sponsor":"Kuopio University Hospital","startDate":"2016-10","conditions":["Cholecystitis, Acute"],"enrollment":200,"completionDate":"2021-12"},{"nctId":"NCT04616352","phase":"","title":"Cefuroxime Resistance in Pyelonephritis","status":"COMPLETED","sponsor":"Universidad Nacional de Colombia","startDate":"2020-12-26","conditions":["Urinary Tract Infections"],"enrollment":973,"completionDate":"2021-07-30"},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":["Osteomyelitis"],"enrollment":11,"completionDate":"2018-11-07"},{"nctId":"NCT03657836","phase":"NA","title":"The Sublimated Mare Milk Supplement's Effect on Gut Mucosal Lining After Antibiotics","status":"COMPLETED","sponsor":"Nazarbayev University Medical Center","startDate":"2018-08-01","conditions":["Acute Bronchitis"],"enrollment":12,"completionDate":"2020-12-01"},{"nctId":"NCT04212078","phase":"PHASE1,PHASE2","title":"Intracameral Levofloxacin (0.5%) vs Intracameral Cefuroxime","status":"UNKNOWN","sponsor":"National University of Malaysia","startDate":"2019-07-29","conditions":["Endophthalmitis Postoperative"],"enrollment":138,"completionDate":"2022-10"},{"nctId":"NCT03716804","phase":"PHASE4","title":"Establish the Relationship Between Shift in Prescribing Pattern and Associated Shift in Sensitivity Pattern of Causative Microbes in UTI Patients in a Closed Community","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2018-06-06","conditions":["Uncomplicated Urinary Tract Infection","Antibiotic Resistant Infection"],"enrollment":62,"completionDate":"2019-01-31"},{"nctId":"NCT02795949","phase":"PHASE3","title":"Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2016-10","conditions":["Enterobacteriaceae Infections"],"enrollment":344,"completionDate":"2020-01"},{"nctId":"NCT02916134","phase":"NA","title":"Conservative Versus Operative ManageMent of Acute Uncomplicated Appendicitis","status":"COMPLETED","sponsor":"Beaumont Hospital","startDate":"2016-09-12","conditions":["Appendicitis"],"enrollment":186,"completionDate":"2019-12-08"},{"nctId":"NCT01507974","phase":"NA","title":"Examination of the Efficacy of Preventive Antibiotic Treatment During the Puerperium Among Pregnant Women With Recurrent Urinary Tract Infections","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2012-01-16","conditions":["Pregnancy Complications"],"enrollment":220,"completionDate":"2015-01-01"},{"nctId":"NCT04321902","phase":"NA","title":"Empirical Antibiotics in Acute Inflammatory Gallbladder Disease","status":"UNKNOWN","sponsor":"Seoul St. Mary's Hospital","startDate":"2020-04-02","conditions":["Cholecystitis, Acute"],"enrollment":350,"completionDate":"2021-12-30"},{"nctId":"NCT04295122","phase":"PHASE4","title":"Comparing the Effectiveness of Phacoemulsification + ECP Laser and Phacoemulsification Alone for Glaucoma Patients","status":"UNKNOWN","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2020-03-15","conditions":["Glaucoma Open-Angle Primary","Cataract"],"enrollment":160,"completionDate":"2023-03-14"},{"nctId":"NCT02505581","phase":"PHASE4","title":"Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics in Colorectal Surgery Prophylaxis","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2015-05","conditions":["Surgical Wound Infection"],"enrollment":536,"completionDate":"2018-11-10"},{"nctId":"NCT02445859","phase":"PHASE2","title":"Continuous Antibiotic Prophylaxis in Colorectal Surgery","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2015-08","conditions":["Surgical Site Infection"],"enrollment":90,"completionDate":"2017-05"},{"nctId":"NCT02789579","phase":"EARLY_PHASE1","title":"The Preventive Infection Role of One Week Antibiotics Before Minimally Invasive Upper Tract Lithotomy","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2016-09","conditions":["Complication of Surgical Procedure"],"enrollment":150,"completionDate":"2019-12"},{"nctId":"NCT04055233","phase":"PHASE3","title":"Reduction of Postoperative Wound Infections by Antiseptica?","status":"COMPLETED","sponsor":"Johannes Lauscher","startDate":"2015-02-01","conditions":["Surgical Site Infection"],"enrollment":456,"completionDate":"2018-10-20"},{"nctId":"NCT02297815","phase":"","title":"Comparative Effectiveness of Antibiotics for Respiratory Infections","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2014-01","conditions":["Acute Otitis Media","Acute Sinusitis","Group A Streptococcal Pharyngitis"],"enrollment":2472,"completionDate":"2016-04"},{"nctId":"NCT04009772","phase":"PHASE2,PHASE3","title":"Single Dose Cefepime Versus Cefuroxime Plus Metronidazole as a Prophylactic Antibiotic During Emergency Intrapartum Cesarean Section","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-07-01","conditions":["Emergency Cesarean Section","Infection Wound"],"enrollment":500,"completionDate":"2020-03-01"},{"nctId":"NCT01659866","phase":"PHASE4","title":"Antibiotic Prophylaxis for Transrectal Prostate Biopsy","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2012-08","conditions":["Infection"],"enrollment":563,"completionDate":"2016-08"},{"nctId":"NCT03980015","phase":"","title":"Inflammatory Responses in Solitary and Multiple Erythema Migrans","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2006-06-01","conditions":["Erythema Migrans"],"enrollment":134,"completionDate":"2019-05-31"},{"nctId":"NCT02147249","phase":"NA","title":"Cytokines and Chemokines in Erythema Migrans","status":"UNKNOWN","sponsor":"University Medical Centre Ljubljana","startDate":"2013-07","conditions":["Erythema Migrans"],"enrollment":150,"completionDate":"2020-12-31"},{"nctId":"NCT02850250","phase":"","title":"Pharmacokinetics of Post Operative Cefuroxime in Infants Undergoing Cardiac Surgery","status":"WITHDRAWN","sponsor":"Alder Hey Children's NHS Foundation Trust","startDate":"2018-07","conditions":["Cardiac Event"],"enrollment":0,"completionDate":"2019-10"},{"nctId":"NCT03754387","phase":"NA","title":"Antibiotic Therapy vs Laparscopic Appendectomy in Pediatric Chronic Appendicitis","status":"UNKNOWN","sponsor":"Zunyi Medical College","startDate":"2019-01-01","conditions":["Chronic Appendicitis"],"enrollment":200,"completionDate":"2022-01-01"},{"nctId":"NCT03014687","phase":"PHASE4","title":"Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions","status":"RECRUITING","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2017-07-01","conditions":["Antibiotics","Pituitary Adenoma"],"enrollment":116,"completionDate":"2019-07"},{"nctId":"NCT02515565","phase":"NA","title":"Physiotherapy in Patients Hospitalized Due to Pneumonia.","status":"UNKNOWN","sponsor":"Universidad de Granada","startDate":"2015-09","conditions":["Pneumonia"],"enrollment":60,"completionDate":"2018-07"},{"nctId":"NCT03584919","phase":"NA","title":"Comparison of Doxycycline and Cefuroxime Axetil in Erythema Migrans","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2006-06-01","conditions":["Erythema Chronicum Migrans"],"enrollment":509,"completionDate":"2007-09-30"},{"nctId":"NCT03221504","phase":"NA","title":"7-day Compared With 10-day Antibiotic Treatment for Febrile Urinary Tract Infections in Children","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2018-01-01","conditions":["Urinary Tract Infections in Children"],"enrollment":221,"completionDate":"2020-01-31"},{"nctId":"NCT03141476","phase":"PHASE4","title":"Adequacy of Perioperative Cefuroxime Dosage According to the BMI","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2017-03-01","conditions":["Obesity; Drug"],"enrollment":60,"completionDate":"2017-12-12"},{"nctId":"NCT03020940","phase":"","title":"The Clinical Trial of Cefuroxime Axetil Dispersible Tablets","status":"UNKNOWN","sponsor":"Jiangsu Famous Medical Technology Co., Ltd.","startDate":"2017-01","conditions":["Infectious Disease"],"enrollment":100000,"completionDate":"2019-11"},{"nctId":"NCT02819570","phase":"PHASE4","title":"Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes","status":"UNKNOWN","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2015-11","conditions":["Premature Rupture of Membrane"],"enrollment":400,"completionDate":"2017-12"},{"nctId":"NCT01790529","phase":"PHASE4","title":"Randomized Controlled Trial to Evaluate the Optimal Timing of Surgical Antimicrobial Prophylaxis","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2013-02","conditions":["Surgical Site Infection"],"enrollment":5000,"completionDate":"2016-09"},{"nctId":"NCT00497341","phase":"PHASE4","title":"Antibiotic Prophylaxis in Total Knee Prosthesis","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2008-01","conditions":["Infection"],"enrollment":1332,"completionDate":"2010-08"},{"nctId":"NCT00136344","phase":"NA","title":"Study of Antibiotic Prophylaxis for Endophthalmitis Following Cataract Surgery","status":"COMPLETED","sponsor":"City, University of London","startDate":"2003-09","conditions":["Endophthalmitis"],"enrollment":35000,"completionDate":"2006-05"},{"nctId":"NCT01259141","phase":"NA","title":"The Optimization of Mycoplasm Pneumonia Antibiotic Therapy","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2010-10","conditions":["Mycoplasma Pneumonia"],"enrollment":208,"completionDate":"2014-12"},{"nctId":"NCT02436083","phase":"PHASE4","title":"Antibiotics in Free Flaps Reconstructions","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2007-07","conditions":["Postoperative Infection"],"enrollment":350,"completionDate":"2014-12"},{"nctId":"NCT02009098","phase":"PHASE4","title":"RCT of Postoperative Infections Following Caesarean Section Infections Following Caesarean Section","status":"WITHDRAWN","sponsor":"Odense University Hospital","startDate":"2014-10","conditions":["Postoperative Infection"],"enrollment":0,"completionDate":"2016-06"},{"nctId":"NCT02162134","phase":"NA","title":"Does Sugared or Sugar Free Chewing Gum Reduces Postoperative Ileus After Laparoscopic Cholecystectomy","status":"COMPLETED","sponsor":"Benazir Bhutto Hospital, Rawalpindi","startDate":"2013-01","conditions":["Postoperative Ileus."],"enrollment":90,"completionDate":"2014-02"},{"nctId":"NCT01587768","phase":"","title":"WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11","conditions":["Infections, Bacterial"],"enrollment":1,"completionDate":"2014-07"},{"nctId":"NCT01283815","phase":"PHASE2","title":"Laparoscopic Management of Periappendicular Abscess","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2011-01","conditions":["Appendicitis","Abdominal Abscess"],"enrollment":60,"completionDate":"2014-08"},{"nctId":"NCT02171338","phase":"PHASE4","title":"Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections","status":"UNKNOWN","sponsor":"Holbaek Sygehus","startDate":"2013-10","conditions":["Pneumonia","Acute Exacerbation of Chronic Obstructive Airways Disease"],"enrollment":55,"completionDate":"2014-09"},{"nctId":"NCT02072798","phase":"PHASE4","title":"Antibiotics and Gut Microbiota Among Newborn Infants","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2014-02","conditions":["Surgical Wound Infection","Infection; Cesarean Section","Complications; Cesarean Section"],"enrollment":42,"completionDate":"2014-08"},{"nctId":"NCT01434173","phase":"","title":"Risk of Acute Liver Injury in Users of Antimicrobials","status":"COMPLETED","sponsor":"Bayer","startDate":"2001-07","conditions":["Drug-Induced Liver Injury"],"enrollment":1299056,"completionDate":"2009-03"},{"nctId":"NCT02169856","phase":"NA","title":"Role of Emotional Freedom Techniques in Reducing Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy","status":"COMPLETED","sponsor":"Benazir Bhutto Hospital, Rawalpindi","startDate":"2013-07","conditions":["Postoperative Nausea and Vomiting"],"enrollment":50,"completionDate":"2014-02"},{"nctId":"NCT00492973","phase":"NA","title":"Do Corticosteroid Injections During Total Knee Replacement Improve Early Clinical Results?","status":"COMPLETED","sponsor":"New Lexington Clinic","startDate":"2006-03","conditions":["Osteoarthritis","Post-traumatic; Arthrosis"],"enrollment":101,"completionDate":"2008-02"},{"nctId":"NCT00818610","phase":"PHASE4","title":"Monotherapy Versus Bitherapy in Non-severe Hospitalized Community-acquired Pneumonia","status":"COMPLETED","sponsor":"Swiss National Fund for Scientific Research","startDate":"2009-01","conditions":["Community-acquired Pneumonia"],"enrollment":601,"completionDate":"2013-04"},{"nctId":"NCT00901628","phase":"PHASE4","title":"Periarticular Multimodal Drug Injections in Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2008-04","conditions":["Osteoarthritis, Knee"],"enrollment":101,"completionDate":"2009-04"},{"nctId":"NCT00613769","phase":"PHASE4","title":"Orally Administered Trimethoprim-sulfamethoxazole and Metronidazole as Prophylaxis of Infection Following Elective Colorectal Surgery","status":"COMPLETED","sponsor":"Halmstad County Hospital","startDate":"2007-09","conditions":["Infection Prophylaxis in Colo Rectal Surgery"],"enrollment":1073,"completionDate":"2012-05"},{"nctId":"NCT01080963","phase":"PHASE4","title":"Daptomycin as Antibiotic Prophylaxis of Sternal Wound Infections","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2008-11","conditions":["Wound Infection"],"enrollment":650,"completionDate":"2012-03"},{"nctId":"NCT01524081","phase":"PHASE3","title":"Antibiotic Prophylaxis in the Prevention of Surgical Site Infections After Selected Urgent Abdominal Surgical Procedures","status":"COMPLETED","sponsor":"The Faculty Hospital Na Bulovce","startDate":"2008-07","conditions":["Acute Appendicitis","Perforated Gastroduodenal Ulcer","Small Bowel Obstruction"],"enrollment":187,"completionDate":"2011-11"},{"nctId":"NCT01518192","phase":"PHASE4","title":"Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2006-06","conditions":["Erythema Migrans","Post-Lyme Disease Symptoms"],"enrollment":544,"completionDate":"2009-01"},{"nctId":"NCT01372371","phase":"NA","title":"Efficacy of Local Powder Prophylactics","status":"UNKNOWN","sponsor":"Ganga Hospital","startDate":"2011-06","conditions":["Infection"],"enrollment":1844,"completionDate":"2013-06"},{"nctId":"NCT00269932","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Cefuroxime Axetil in the Treatment of Adults With Persistent Bronchitis Experiencing Rapid Onset of Severe Worsening of Symptoms Caused by Bacteria","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1993-08","conditions":["Bronchitis, Chronic"],"enrollment":485,"completionDate":"1994-05"},{"nctId":"NCT00257049","phase":"PHASE2,PHASE3","title":"A Study of the Safety and Effectiveness of Levofloxacin Compared With Ceftriaxone Sodium or Cefuroxime Axetil in the Treatment of Adults With Pneumonia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1984-01","conditions":["Pneumonia"],"enrollment":604,"completionDate":"1995-01"},{"nctId":"NCT00132938","phase":"PHASE4","title":"PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-01","conditions":["Chronic Bronchitis"],"enrollment":5660,"completionDate":"2006-05"},{"nctId":"NCT01237730","phase":"NA","title":"Tailored Antibiotics Prophylaxis for Percutaneous Endoscopic Gastrostomy","status":"UNKNOWN","sponsor":"National Cheng Kung University","startDate":"2010-07","conditions":["The Patients Who Receive Percutaneous Endoscopic Gastrostomy","Peristomal Wound Infection After the Operation of PEG","Prophylactic Antibiotics Before PEG"],"enrollment":100,"completionDate":"2011-08"},{"nctId":"NCT01228825","phase":"","title":"Pharmacokinetics of Cefuroxime in Cardiac Surgery With Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2007-05","conditions":["Cardiac Surgery"],"enrollment":19,"completionDate":"2008-04"},{"nctId":"NCT00557453","phase":"","title":"The Role of Antibiotic Treatment in Patients With Acute Mild Cholecystitis - A Prospective Randomized Controlled Trial","status":"COMPLETED","sponsor":"Hadassah Medical Organization","startDate":"2008-04","conditions":["Acute Cholecystitits"],"enrollment":120,"completionDate":"2010-04"},{"nctId":"NCT01138852","phase":"PHASE4","title":"Ampicillin/Sulbactam Versus Cefuroxime as Antimicrobial Prophylaxis for Cesarean Section","status":"COMPLETED","sponsor":"Attikon Hospital","startDate":"2004-07","conditions":["Surgical Site Infections"],"enrollment":176,"completionDate":"2008-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Injection","formulations":[{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"Cefuroxime"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAVENOUS","productName":"Cefuroxime"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAVENOUS","productName":"Cefuroxime sodium"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Cefuroxime and Dextrose"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147760","MMSL":"2973","NDDF":"002731","UNII":"O1R9FJ93ED","VUID":"4019668","CHEBI":"CHEBI:3515","VANDF":"4017551","INN_ID":"3902","RXNORM":"204144","UMLSCUI":"C0007562","chemblId":"CHEMBL2146124","ChEMBL_ID":"CHEMBL2146124","KEGG_DRUG":"D00262","DRUGBANK_ID":"DB01112","PDB_CHEM_ID":" KOV","PUBCHEM_CID":"5479529","SNOMEDCT_US":"372833007","IUPHAR_LIGAND_ID":"10900","SECONDARY_CAS_RN":"56238-63-2","MESH_DESCRIPTOR_UI":"D002444"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1983-","companyName":"Covis Injectables","relationship":"Original Developer"},{"period":"present","companyName":"GSK","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.1 hours","clearance":"2.2 mL/min/kg","bioavailability":"32%","volumeOfDistribution":"0.15 L/kg"},"publicationCount":5501,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"J01DC02","allCodes":["J01DC02","J01RA03","S01AA27"]},"biosimilarFilings":[],"originalDeveloper":"Covis Injectables","recentPublications":[{"date":"2026 Mar 28","pmid":"41902618","title":"Detection of Listeria monocytogenes from Raw Milk (Nono) in Cows Using Polymerase Chain Reaction.","journal":"Foodborne pathogens and disease"},{"date":"2026 Mar 12","pmid":"41892449","title":"Analysis of Antibiotic Consumption Trends and Pathogens' Epidemiological Profile Within a Multidisciplinary Clinical Hospital from Romania.","journal":"Antibiotics (Basel, Switzerland)"},{"date":"2026 Mar 27","pmid":"41891536","title":"Investigation of interactions between LDPE containers and ingredients of oil-based ophtalmic formulations.","journal":"Polimery w medycynie"},{"date":"2026","pmid":"41867320","title":"Case Report: Maculopathy following standard dose intracameral cefuroxime injection during ICL surgery.","journal":"Frontiers in ophthalmology"},{"date":"2026 Mar 20","pmid":"41860599","title":"Dual-mode carbon dots for cefuroxime monitoring in plasma.","journal":"Mikrochimica acta"}],"companionDiagnostics":[],"genericManufacturers":10,"_genericFilersChecked":true,"genericManufacturerList":["Alkem Labs Ltd","Anda Repository","Ani Pharms","Apotex","Aurobindo Pharma","Chartwell Rx","Fosun Pharma","Lupin","Ranbaxy Labs Ltd","Sun Pharm Inds Ltd"],"status":"approved","companyName":"Glaxosmithkline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"1983","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1983-10-19T00:00:00.000Z","mah":"COVIS INJECTABLES","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2004-06-29T00:00:00.000Z","mah":"B BRAUN","brand_name_local":null,"application_number":"NDA050780"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2007-12-21T00:00:00.000Z","mah":"AUROBINDO PHARMA","brand_name_local":null,"application_number":"ANDA065308"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2008-08-25T00:00:00.000Z","mah":"HIKMA","brand_name_local":null,"application_number":"ANDA065046"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2012-11-21T00:00:00.000Z","mah":"ACS DOBFAR SPA","brand_name_local":null,"application_number":"ANDA064125"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-03-10T00:00:00.000Z","mah":"ALKEM LABS LTD","brand_name_local":null,"application_number":"ANDA065496"},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:39:07.770308+00:00","fieldsConflicting":3,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}